Honors & Awards
Zetema Fellowship, Zetema Project (2021-2022)
Fulbright Scholarship, US-UK Fulbright Commission (2018-2019)
Education & Certifications
MSc, London School of Economics and Political Science, International Health Policy, Distinction (2019)
BSc, University of Richmond, Biochemistry & Molecular Biology, Summa Cum Laude (2017)
- Strategies to Overcome the Market Dominance of Hospitals-Reply. JAMA 2021; 326 (3): 278-279
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
Health policy (Amsterdam, Netherlands)
Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed.
View details for DOI 10.1016/j.healthpol.2021.03.013
View details for PubMedID 33820678
- Overcoming the Market Dominance of Hospitals. JAMA 2021
- Public Benefit Corporations: A Third Option For Health Care Delivery? Health Affairs 2021
- Rating The Medicare Advantage Star Ratings—Improving The Status Quo Health Affairs 2021
The Economic Footprint of Interventional Radiology in the United States: Implications for Systems Development.
Journal of the American College of Radiology : JACR
PURPOSE: Despite the growing presence of interventional radiology (IR) in inpatient care, its global impact on the health care system remains uncharacterized. The aim of this study was to quantitate the use of IR services rendered to hospitalized patients in the United States and the impact on cost.METHODS: The National Inpatient Sample 2016 was queried. Using the International Classification of Diseases, tenth rev, Clinical Modification/Procedure Classification System, adult inpatients who underwent routine IR procedures were identified. Unadjusted and adjusted analyses were performed. Weighted patient data are presented to provide national estimates.RESULTS: Of the 29.7 million inpatient admissions in 2016, 2.3 million (7.8%) had at least one IR procedure. Patients who needed IR were older (62.8 vs 57.1 years, P < .001), were sicker on the basis of the All Patient Refined Diagnosis Related Groups (27% major or extreme vs 14% for non-IR, P < .001), and had higher inpatient mortality (8.2% vs 1.7%, P < .001). While representing 7.8% of all admissions, this cohort accounted for 18.4% ($68.4 billion) of adult inpatient health care costs and about 3 times higher mean hospitalization cost compared with other inpatients ($29,402 vs $11,062, P < .001), which remained significant even after controlling for age and All Patient Refined Diagnosis Related Group.CONCLUSIONS: Approximately 1 in 10 US inpatients are treated with IR during their hospitalizations. These patients are sicker, with about 4 times higher mortality and 2.5 times greater length of stay, accounting for almost one-fifth of all health care costs. These findings suggest that IR should have a voice in discussions of means to save costs and improve patient outcomes in the United States.
View details for DOI 10.1016/j.jacr.2020.07.038
View details for PubMedID 32918863
- The Case for Independent Centers for Disease Control and Prevention—Protecting Public Health from Politics JAMA Health Forum 2020; 1 (9)
- What If We Gave Hospitals Real Incentives To Prepare For The Next Pandemic? Health Affairs 2020
- How To Ensure COVID-19 Doesn’t Delay Value-Based Care Health Affairs 2020
- MACRA and Medicare's Elusive Quest for Fairness and Value with Physician Payment Policy: Speeding up the Transition to Big Med Saint Louis University Journal of Health Law & Policy 2018; 11 (2): 235-248
A molecular dynamics study of the binary complexes of APP, JIP1, and the cargo binding domain of KLC
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
2017; 85 (2): 221–34
Mutations in the amyloid precursor protein (APP) are responsible for the formation of amyloid-β peptides. These peptides play a role in Alzheimer's and other dementia-related diseases. The cargo binding domain of the kinesin-1 light chain motor protein (KLC1) may be responsible for transporting APP either directly or via interaction with C-jun N-terminal kinase-interacting protein 1 (JIP1). However, to date there has been no direct experimental or computational assessment of such binding at the atomistic level. We used molecular dynamics and free energy estimations to gauge the affinity for the binary complexes of KLC1, APP, and JIP1. We find that all binary complexes (KLC1:APP, KLC1:JIP1, and APP:JIP1) contain conformations with favorable binding free energies. For KLC1:APP the inclusion of approximate entropies reduces the favorability. This is likely due to the flexibility of the 42-residue APP protein. In all cases we analyze atomistic/residue driving forces for favorable interactions. Proteins 2017; 85:221-234. © 2016 Wiley Periodicals, Inc.
View details for DOI 10.1002/prot.25208
View details for Web of Science ID 000394519300003
View details for PubMedID 27891669